OTLK (Outlook Therapeutics) Notes Receivable: $0.00 Mil (As of Mar. 2026)


OTLK Outlook Therapeutics Inc OTLK
17 GF Score
Price $1.45
! 5 Warning Signs
View Full Analysis

What is Outlook Therapeutics Notes Receivable?

Outlook Therapeutics OTLK -1.69% 17 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 17/100. The stock has 5 warning signs investors should review.

Outlook Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Outlook Therapeutics Notes Receivable Related Terms

Outlook Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Notes Receivable Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OTLK
17GF Score
Outlook Therapeutics Inc OTLK
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Outlook Therapeutics (OTLK) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Outlook Therapeutics and its competitors.
Is Outlook Therapeutics' Notes Receivable too high?
Outlook Therapeutics' current Notes Receivable is $0.00 Mil. Overall, Outlook Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Notes Receivable compare to FULC and OBIO?
Outlook Therapeutics' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Outlook Therapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
17GF Score

Get the complete analysis for OTLK

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.45
Price